National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)

Author:

Rath Eva,Bonelli Michael,Duftner Christina,Gruber Johann,Mandl Peter,Moazedi-Furst Florentine,Pieringer Herwig,Puchner Rudolf,Flick Holger,Salzer Helmut J. F.,Weiss Günter,Winkler Stefan,Skvara Hans,Moschen Alexander,Hofer Harald,Feurstein Julia,Sautner JudithORCID

Abstract

SummaryThis publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.

Funder

Medical University of Vienna

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Reference46 articles.

1. Consensus Statement 2011 Österreichische Ärztezeitung. https://infektiologie.co.at/wp-content/uploads/2017/08/cs-tbc_u_biologika.pdf. Accessed 15 Aug 2022.

2. WHO-Global Tuberculosis Report. 2020. https://www.who.int/publications/i/item/9789240013131. Accessed 15 Aug 2022.

3. https://www.ages.at/themen/krankheitserreger/tuberkulose-tbc/. Accessed 15 Aug 2022.

4. WHO, editor. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.

5. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of Rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–6. https://doi.org/10.3899/jrheum.150051.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3